Cognition Therapeutics Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Cognition Therapeutics şirketinin kazançları yıllık ortalama -15.5% oranında azalırken, Pharmaceuticals sektörünün kazançları yıllık 9.7% oranında arttı.
Anahtar bilgiler
-15.54%
Kazanç büyüme oranı
76.67%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 5.95% |
| Gelir büyüme oranı | n/a |
| Özkaynak getirisi | -57.12% |
| Net Marj | n/a |
| Son Kazanç Güncellemesi | 31 Mar 2026 |
Yakın geçmiş performans güncellemeleri
Recent updates
Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
DLB Psychosis Program And Biomarker Strategy Will Shape Long Term Upside Potential
Catalysts About Cognition Therapeutics Cognition Therapeutics is a clinical stage biopharmaceutical company focused on developing zervimesine for neurodegenerative diseases such as dementia with Lewy bodies and Alzheimer's disease. What are the underlying business or industry changes driving this perspective?We're Keeping An Eye On Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, Cognition...We're A Little Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Cognition Therapeutics (NASDAQ:CGTX) Will Have To Spend Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Can Cognition Therapeutics (NASDAQ:CGTX) Afford To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Cognition Therapeutics: Shines Less Bright After Phase 2 Results In Alzheimer's Disease
Summary Cognition Therapeutics' stock dropped over 40% after Phase 2 trial results for Alzheimer's disease. Results showed cognitive benefit but fading statistical significance over time. CT1812 did not outperform placebo on all rating scales over 3-6 months, raising concerns for future milestones and larger trials. Financial reliance on NIH grants poses risks, and ongoing trials in dementia with Lewy Bodies, Alzheimer's and dry AMD have the potential for further stock decline. Read the full article on Seeking AlphaIs Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's
Summary Cognition Therapeutics is set to report topline data from its Phase 2 trial in Alzheimer's disease in mid-2024. CT1812, the company's lead drug candidate, is a sigma-2 receptor antagonist for Alzheimer's and aims to prevent the binding of toxic Aβ oligomers. Preliminary data from the ongoing SHINE trial showed some interesting results, but were not consistent with other previous studies, raising caution about the upcoming data. At a ~$70 million market cap with about half of that cash, the topline readout could be a binary event for the stock. Read the full article on Seeking AlphaHere's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Cognition Therapeutics (NASDAQ:CGTX) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Cognition stock rises 12% on $2.14M grant from NIH for Alzheimer's study
Cognition Therapeutics (NASDAQ:CGTX) said it received a $2.14M grant from the National Institute on Aging (NIA) to help complete an ongoing study of CT1812 in adults with mild-to-moderate Alzheimer's disease. The study called SEQUEL will evaluate if CT1812 results in a normalization of the EEG patterns. The trial is enrolling 16 adults who will receive either CT1812 or placebo, the company said in a Sept. 27 press release. Cognition noted that the study is taking place at the Amsterdam UMC Dept. of Neurology/Alzheimer Center and Brain Research Center. The NIA, a division of the National Institutes of Health (NIH), awarded a $3.2M grant in 2020 to support the study and has now awarded $2.14M, the company added. CGTX +12.28% to $1.92 premarket Sept. 27We Think Cognition Therapeutics (NASDAQ:CGTX) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Cognition's Alzheimer's candidate demonstrates mechanism of action; shares soar
An analysis of biomarker data from Cognition Therapeutics' (NASDAQ:CGTX) Alzheimer's disease candidate CT1812 indicate the oral once-daily treatment supports a synaptoprotective mechanism of action and has a role in normalizing cellular processes. Proteomic analyses demonstrated CT1812's impact on several Alzheimer's biomarkers, including YKL-40, which is an indicator of inflammation and is upregulated in the disease. Results showed that participants given CT-1812 saw declining levels of YKL-40. The candidate also had a significant impact on cerebrospinal fluid levels of clusterin, a genetic risk factor for Alzheimer's. Cognition closed up 62% on Thursday but is down 16% in Friday premarket trading.We're Not Very Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Gelir ve Gider Dağılımı
Cognition Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 31 Mar 26 | 0 | -20 | 10 | 33 |
| 31 Dec 25 | 0 | -23 | 11 | 37 |
| 30 Sep 25 | 0 | -28 | 11 | 34 |
| 30 Jun 25 | 0 | -33 | 11 | 42 |
| 31 Mar 25 | 0 | -33 | 12 | 42 |
| 31 Dec 24 | 0 | -34 | 12 | 42 |
| 30 Sep 24 | 0 | -34 | 13 | 45 |
| 30 Jun 24 | 0 | -31 | 13 | 45 |
| 31 Mar 24 | 0 | -29 | 14 | 42 |
| 31 Dec 23 | 0 | -26 | 14 | 37 |
| 30 Sep 23 | 0 | -23 | 13 | 32 |
| 30 Jun 23 | 0 | -23 | 14 | 29 |
| 31 Mar 23 | 0 | -24 | 14 | 29 |
| 31 Dec 22 | 0 | -21 | 13 | 30 |
| 30 Sep 22 | 0 | -24 | 17 | 29 |
| 30 Jun 22 | 0 | -22 | 14 | 25 |
| 31 Mar 22 | 0 | -19 | 12 | 21 |
| 31 Dec 21 | 0 | -16 | 10 | 19 |
| 30 Sep 21 | 0 | -12 | 5 | 16 |
| 30 Jun 21 | 0 | -10 | 4 | 16 |
| 31 Mar 21 | 0 | -9 | 4 | 14 |
| 31 Dec 20 | 0 | -12 | 5 | 13 |
Kaliteli Kazançlar: CGTX şu anda kârlı değil.
Büyüyen Kar Marjı: CGTX şu anda kârlı değil.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: CGTX kârlı değildir ve zararlar son 5 yılda yılda 15.5% oranında artmıştır.
Büyüme Hızlandırma: CGTX 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil
Kazançlar vs. Sektör: CGTX kârlı olmadığından, geçmiş yıl kazanç büyümesinin Pharmaceuticals sektörüyle ( -5% ) karşılaştırılması zorlaşıyor.
Özkaynak Getirisi
Yüksek ROE: CGTX hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -57.12% ) sahiptir.
Varlık Getirisi
Kullanılan Sermaye Getirisi
Geçmişte güçlü performans gösteren şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/22 18:05 |
| Gün Sonu Hisse Fiyatı | 2026/05/22 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Cognition Therapeutics, Inc. 7 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| null null | B. Riley Securities, Inc. |
| William Wood | B. Riley Securities, Inc. |